Montag & Associates
PTGX icon

Montag & Associates’s Protagonist Therapeutics PTGX Stock Holding History

Montag & Associates’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25
Closed -$1.66K – 1120
2025
Q3 		$1.66K Buy
+25
New +$1.42K ﹤0.01% 943

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Montag & Associates's PTGX Position: Q4 2025 in Review

Montag & Associates sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 25 shares — an estimated $1.66K sold.

Montag & Associates first reported a position in PTGX in Q3 2025 and held it in 1 quarter. The position peaked at $1.66K in Q3 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Montag & Associates reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Montag & Associates sold 25 Protagonist Therapeutics shares in Q4 2025, an estimated $1.66K.
  • Montag & Associates first reported a position in Protagonist Therapeutics in Q3 2025 and held it in 1 quarter.
  • Montag & Associates's Protagonist Therapeutics position peaked at $1.66K in Q3 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.